Talvey Talquetamab GPRC5D Bispecific Multiple Myeloma Review 2026
Author: Critical Kare PharmaMyeloma & Bispecific Desk
On October 20, 2026, international myeloma consortiums highlighted Talvey® (Talquetamab-tgvs 3 mg/1.5 mL and 40 mg/mL subcutaneous injection) by Janssen as a first-in-class bispecific antibody targeting GPRC5D.
By targeting G protein-coupled receptor class C group 5 member D (GPRC5D)—an antigen highly expressed on plasma cells independent of BCMA—Talvey provides deep, durable responses in multiple myeloma patients who have relapsed following prior BCMA-directed CAR-T or bispecific therapies.
Through Critical Kare Pharma, certified genuine manufacturer supplies of Talvey Talquetamab Subcutaneous Injection are supplied internationally under validated 2°C–8°C cold-chain custody.
The MonumenTAL-1 Clinical Milestones
- Exceptional Response Rates: Overall response rate exceeding 73% across both weekly (0.4 mg/kg) and biweekly (0.8 mg/kg) subcutaneous dosing cohorts.
- Prior BCMA Exposure: ORR of 63.2% in patients who had failed prior BCMA CAR-T cell or antibody therapies, overcoming antigen loss.
- Step-Up Priming Regimen: Administered with step-up doses (0.01 mg/kg and 0.06 mg/kg) alongside corticosteroid and antihistamine premedication to prevent severe CRS.
Global Cold-Chain Access via Critical Kare Pharma
Coordinated under international named-patient import corridors with digital temperature data logging.
